South Korea-based Hanmi Pharmaceutical has signed a supply agreement with global healthcare company Organon to export three finished combination products in the cardiovascular and respiratory therapeutic areas to Malaysia and the Philippines, expanding the companies' partnership in Southeast Asia, according to BioSpectrum Asia.

Under the agreement, Hanmi will supply the combination medicines while Organon assumes responsibility for marketing, distribution, and sales across both local markets. The two companies plan to pursue phased regulatory approvals and product launches, with the potential to expand their collaboration over the mid to long term.

Southeast Asia is widely regarded as a rapidly growing pharmaceutical market, driven by population growth and the increasing prevalence of chronic diseases. Demand for combination therapies is rising in particular as the number of patients managing chronic conditions such as hypertension continues to grow across the region.

Organon, established in 2021, operates a portfolio of over 70 products across multiple therapeutic areas and distributes medicines and devices across more than 140 markets globally, including an established commercial presence in Southeast Asia.

Hanmi Pharmaceutical has built a track record of global partnerships with multinational pharmaceutical companies, and the Organon agreement is expected to support the company's commercial expansion in the Southeast Asian market by leveraging Organon's established regional distribution network and local market expertise.

The agreement reflects broader industry momentum toward partnership-driven market entry strategies in Southeast Asia, where regulatory complexity and market fragmentation make established local commercial partners a critical enabler of pharmaceutical growth.

Access the full coverage for further detail on the Hanmi Pharmaceutical and Organon supply agreement and Southeast Asia expansion plans.